Tech Company Financing Transactions
Ambrx Funding Round
5AM Ventures and Tavistock Life Sciences participated in a $12.5 million Series A venture round for Ambrx. The funding round was announced on 9/22/2003.
Transaction Overview
Company Name
Announced On
9/22/2003
Transaction Type
Venture Equity
Amount
$12,500,000
Round
Series A
Investors
5AM Ventures (Lead Investor) (John Diekman)
Proceeds Purpose
Discovery and development of several Lilly drugs, including Humulin(R), Humatrope(R), Evista(R), Xigris(R), and Forteo(R).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10975 North Torrey Pines Rd.
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Ambrx is a biopharmaceutical company that develops protein therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Feng Tian
Chief Medical Officer
Joy Yan
Vice President
Sukumar Sakamuri
VP - Bus. Development
Simon Allen
VP - Bus. Development
Ying Buechler
VP - Finance
Dana Zhang
VP - R & D
Shawn Zhang
Browse more venture capital transactions:
Prev: 9/22/2003: RadioFrame Networks venture capital transaction
Next: 9/22/2003: Nuasis venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs